Results 1 to 2 of 2

Thread: Acorda therapeutics Announces Data On Ampyra (Dalfampridine) Presented at 26th Congre

  1. #1

    Acorda therapeutics Announces Data On Ampyra (Dalfampridine) Presented at 26th Congre

    Acorda therapeutics Announces Data On Ampyra (Dalfampridine) Presented at 26th Congress of European Committee for Treatment and Research in Multiple Sclerosis


    Share



    Responders to AMPYRA Showed Clinically Significant and Meaningful Improvement in Walking Ability Based on Recent Consensus Expert Group Criteria



    HAWTHORNE, N.Y.--(BUSINESS WIRE)--Oct 15, 2010 - Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that a new analysis of AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg data examining walking improvement in treatment responders has been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). AMPYRA is an oral medication approved by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

    read...

    http://pharmalive.com/News/Index.cfm?articleid=736529

  2. #2
    Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
    Published: 23:15 EST Thursday the 14th of October 2010 | Press Release by Newswire
    Views - General: 21 / Professonals: 0 / Researchers: 0 / Total: 21 / Stats


    PARIS, October 15, 2010 /PRNewswire-FirstCall/ --

    - Phase III TEMSO Study Meets Goals Including Delayed Disability Progression for Teriflunomide 14mg

    Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p is less than or equal to 0.0005). The risk of disability progression (sustained for 12 weeks) was also significantly reduced by 30% for the 14mg dose (p=0.02) and numerically reduced by 24% for the 7mg dose (p=0.08). Both doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) including serious adverse events or TEAEs leading to treatment discontinuation in the treatment vs. placebo arms.

    To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/Engli...Teriflunomide/

    "We are very pleased with the successful results of the TEMSO study which are an important step forward in multiple sclerosis clinical research," said Marc Cluzel, M.D., Ph.D., Executive Vice President, Research & Development, sanofi-aventis. "These exciting results with teriflunomide represent a new real hope to delivering an oral therapy to patients who live with this serious condition and are eager for new treatment options, and more convenient product forms in-line with our sanofi-aventis commitment to multiple sclerosis."

    The results of the TEMSO trial are the first study findings from a large phase III clinical development program on teriflunomide. These results were presented today during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress, in Gothenburg, Sweden.

    more...

    http://www.bioportfolio.com/news/art...-Patients.html

Similar Threads

  1. Replies: 8
    Last Post: 02-03-2010, 09:21 PM
  2. Replies: 7
    Last Post: 04-18-2007, 09:02 AM
  3. Acorda Therapeutics Announces Pricing of Initial Public Offering
    By Steven Edwards in forum Funding, Legislation, & Advocacy
    Replies: 8
    Last Post: 03-02-2006, 02:34 PM
  4. Replies: 0
    Last Post: 03-19-2003, 12:34 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •